본문바로가기

Respiratory system

메인페이지로 이동
Business
Life Science
ETC
혈액순환개선제
Alvesco Inhaler 80,160
Category
ETC
Indication(s)·Usage
  • Prophylactic treatment of bronchial asthma
Effective components
_ALVESCO INHALER 80:
Ciclesonide 0.17 g (1 spray volume: Ciclesonide 80 μg (total number of sprays: 60 times)
_ALVESCO INHALER 160:
Ciclesonide 0.34 g (1 spray volume: ciclesonide 160 μg (total spray number: 60 times)

Active ingredient(s) and Contents

  • Effective components

    • _ALVESCO INHALER 80:
      Ciclesonide 0.17 g (1 spray volume: Ciclesonide 80 μg (total number of sprays: 60 times)
      _ALVESCO INHALER 160:
      Ciclesonide 0.34 g (1 spray volume: ciclesonide 160 μg (total spray number: 60 times)

  • Other

    • Norflurane, Anhydrous Alcohol

Dosage and administration

  • The drug is for oral inhalation use only.

    Patients should be given an initial dose which is appropriate to the severity of their disease. Symptoms start to improve with this drug within 24 hours of treatment. Once control is achieved, the dose should be individualized and titrated to the minimum dose needed to maintain good asthma control.

    Even if the patient has no symptoms, it should be used regularly, and the administration of this drug should not be suddenly stopped.

    If patients find that the short-acting relief bronchodilator becomes less effective, or if more inhalations are needed than usual, it may be the case that the asthma is not being properly controlled. Please consult a doctor with regards to increasing the drug dose.

    • 1. Adults (12 years of age and older)
      • - mild to moderate asthma: Administer 160 to 320 μg once daily
      • - severe asthma: Administer 320 μg twice daily
      • - In some patients, asthma can be controlled by the maintenance dose 80 μg once daily.
    • 2. pediatric use (6 years to under 12 years of age)
      • - mild to severe asthma: Administer 80 to 160 μg once daily
    • 3. Elderly patients and patients with renal or hepatic impairment: No dose adjustment is necessary.

    • 4. Adults taking oral corticosteroids for long-term (12 years of age and older):
      • - In severe asthma patients who are dependent on oral prednisolone treatment, the recommended dose is 320 to 640 μg twice daily.
      • - When switching from oral steroids to this drug, the patient should be in a relatively stable state. After co-administration with oral steroids at high doses (e.g., 640 μg twice daily) for about 10 days, oral steroids are gradually reduced in weekly intervals to reduce the amount to the lowest possible dose.

    ※ Method of administration

    • 1) If the inhaler is new or has not been used for one week or more, use after releasing three puffs into the air. No shaking is necessary as this is a solution aerosol.
    • 2) The inhaler should be held upright with the thumb on the base below the mouthpiece, remove the mouthpiece cover, close their lips around the mouthpiece, and breathe in slowly and deeply. While breathing in through the mouth, the top of the inhaler should be pressed down.
    • 3) Patients should remove the inhaler from their mouth, and hold their breath for about 10 seconds, or as long as is comfortable. Close the mouthpiece cover.
    • 4) The patient is not to breathe out into the inhaler.
    • 5) The mouthpiece should be cleaned with a dry tissue or cloth weekly. The inhaler should not be washed or put in water.

Storage and handling


  • Airtight container. keep at room temperature (1~25°C)
  • 310 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do
    463-400 Korea [13494]
  • Copyright(c) SK chemicals. All Rights Reserved.

Ethical Management

Site go
GO